{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:14:50Z","timestamp":1780730090750,"version":"3.54.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1TR004398"],"award-info":[{"award-number":["UM1TR004398"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10928-025-09983-6","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T18:29:51Z","timestamp":1752863391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Physiologically-based pharmacokinetic model for predicting drug-drug interactions perpetrated by posaconazole in healthy subjects with normal weight and obesity: Concomitant use and washout"],"prefix":"10.1007","volume":"52","author":[{"given":"Christopher D.","family":"Bruno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elmokadem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Greenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina R.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"9983_CR1","unstructured":"Noxafil [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2024."},{"issue":"S2","key":"9983_CR2","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1002\/jcph.2308","volume":"63","author":"CD Bruno","year":"2023","unstructured":"Bruno CD, Greenblatt DJ, Harmatz JS, Chow CR (2023) Clinical consequences of altered drug disposition in obesity: call for change. J Clin Pharmacol 63(S2):S25\u2013S34. https:\/\/doi.org\/10.1002\/jcph.2308","journal-title":"J Clin Pharmacol"},{"issue":"9945","key":"9983_CR3","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S0140-6736(14)60892-8","volume":"384","author":"K Bhaskaran","year":"2014","unstructured":"Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L (2014) Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5\u00b724 million UK adults. Lancet 384(9945):755\u2013765. https:\/\/doi.org\/10.1016\/S0140-6736(14)60892-8","journal-title":"Lancet"},{"issue":"8","key":"9983_CR4","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","volume":"375","author":"B Lauby-Secretan","year":"2016","unstructured":"Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K (2016) Body fatness and cancer \u2014 Viewpoint of the IARC Working Group. N Engl J Med 375(8):794\u2013798. https:\/\/doi.org\/10.1056\/NEJMsr1606602","journal-title":"N Engl J Med"},{"issue":"2","key":"9983_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s13679-021-00426-0","volume":"10","author":"G Argyrakopoulou","year":"2021","unstructured":"Argyrakopoulou G, Dalamaga M, Spyrou N, Kokkinos A (2021) Gender differences in obesity-related cancers. Curr Obes Rep 10(2):100\u2013115. https:\/\/doi.org\/10.1007\/s13679-021-00426-0","journal-title":"Curr Obes Rep"},{"issue":"1","key":"9983_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13679-023-00542-z","volume":"13","author":"D Tsilingiris","year":"2024","unstructured":"Tsilingiris D, Vallianou NG, Spyrou N et al (2024) Obesity and Leukemia: biological mechanisms, perspectives, and challenges. Curr Obes Rep 13(1):1\u201334. https:\/\/doi.org\/10.1007\/s13679-023-00542-z","journal-title":"Curr Obes Rep"},{"issue":"11","key":"9983_CR7","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1002\/jcph.1257","volume":"58","author":"CR Chow","year":"2018","unstructured":"Chow CR, Harmatz JS, Ryan MJ, Greenblatt DJ (2018) Persistence of a posaconazole-mediated drug-drug interaction with ranolazine after cessation of posaconazole administration: impact of obesity and implications for patient safety. J Clin Pharmacol 58(11):1436\u20131442. https:\/\/doi.org\/10.1002\/jcph.1257","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"9983_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/JCP.0000000000000892","volume":"38","author":"DJ Greenblatt","year":"2018","unstructured":"Greenblatt DJ, Harmatz JS, Ryan MJ, Chow CR (2018) Sustained impairment of lurasidone clearance after discontinuation of posaconazole: impact of obesity, and implications for patient safety. J Clin Psychopharmacol 38(4):289\u2013295. https:\/\/doi.org\/10.1097\/JCP.0000000000000892","journal-title":"J Clin Psychopharmacol"},{"key":"9983_CR9","unstructured":"Ranexa [package insert] (2019) Gilead Sciences, Inc., Foster City, CA"},{"key":"9983_CR10","unstructured":"Latuda [package insert] (2019) Sunovion Pharmaceuticals, Inc., Marlborough, MA"},{"issue":"4","key":"9983_CR11","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/jcph.2180","volume":"63","author":"T Iwasa","year":"2023","unstructured":"Iwasa T, de Almeida C, Fauchet F et al (2023) Model-informed dose justifications of posaconazole in Japanese patients for prophylaxis and treatment against fungal infection. J Clin Pharmacol 63(4):421\u2013434. https:\/\/doi.org\/10.1002\/jcph.2180","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"9983_CR12","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/jac\/dkz546","volume":"75","author":"RE Wasmann","year":"2020","unstructured":"Wasmann RE, Smit C, van Donselaar MH et al (2020) Implications for IV posaconazole dosing in the era of obesity. J Antimicrob Chemother 75(4):1006\u20131013. https:\/\/doi.org\/10.1093\/jac\/dkz546","journal-title":"J Antimicrob Chemother"},{"key":"9983_CR13","unstructured":"Rohatgi A (2019) WebPlotDigitizer.\u00a0https:\/\/automeris.io, Version 4"},{"issue":"2","key":"9983_CR14","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1128\/AAC.04223-14","volume":"59","author":"WM Kersemaekers","year":"2015","unstructured":"Kersemaekers WM, van Iersel T, Nassander U et al (2015) Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects. Antimicrob Agents Chemother 59(2):1246\u20131251. https:\/\/doi.org\/10.1128\/AAC.04223-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"9983_CR15","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/j.1540-8167.2008.01246.x","volume":"19","author":"AJ Moss","year":"2008","unstructured":"Moss AJ, Zareba W, Schwarz KQ, Rosero S, Mcnitt S, Robinson JL (2008) Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 Long-QT syndrome. J Cardiovasc Electrophysiol 19(12):1289\u20131293. https:\/\/doi.org\/10.1111\/j.1540-8167.2008.01246.x","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"1","key":"9983_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40256-013-0006-7","volume":"13","author":"QY Tan","year":"2013","unstructured":"Tan QY, Li HD, Zhu RH, Zhang QZ, Zhang J, Peng WX (2013) Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, latin square design, Phase I study. Am J Cardiovasc Drugs 13(1):17\u201325. https:\/\/doi.org\/10.1007\/s40256-013-0006-7","journal-title":"Am J Cardiovasc Drugs"},{"issue":"9","key":"9983_CR17","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s40261-017-0546-8","volume":"37","author":"C Hu","year":"2017","unstructured":"Hu C, Wang Y, Song R, Yu C, Luo X, Jia J (2017) Single- and multiple-dose pharmacokinetics, safety and tolerability of lurasidone in healthy Chinese subjects. Clin Drug Investig 37(9):861\u2013871. https:\/\/doi.org\/10.1007\/s40261-017-0546-8","journal-title":"Clin Drug Investig"},{"issue":"12","key":"9983_CR18","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1016\/j.clinthera.2015.11.001","volume":"37","author":"RL Findling","year":"2015","unstructured":"Findling RL, Goldman R, Chiu YY et al (2015) Pharmacokinetics and tolerability of lurasidone in children and adolescents with psychiatric disorders. Clin Ther 37(12):2788\u20132797. https:\/\/doi.org\/10.1016\/j.clinthera.2015.11.001","journal-title":"Clin Ther"},{"issue":"9","key":"9983_CR19","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/jps.24690","volume":"105","author":"B Hens","year":"2016","unstructured":"Hens B, Brouwers J, Corsetti M, Augustijns P (2016) Supersaturation and precipitation of posaconazole upon entry in the upper small intestine in humans. JPharmSci 105(9):2677\u20132684. https:\/\/doi.org\/10.1002\/jps.24690","journal-title":"JPharmSci"},{"key":"9983_CR20","doi-asserted-by":"publisher","unstructured":"Cleary Y, Gertz M, Morcos PN, et al. Model-based assessments of CYP-mediated drug\u2013drug interaction risk of alectinib: physiologically based pharmacokinetic modeling supported clinical development. Clin Pharmacol Ther. Published online December 27, 2017:n\/a-n\/a. https:\/\/doi.org\/10.1002\/cpt.956","DOI":"10.1002\/cpt.956"},{"issue":"11","key":"9983_CR21","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.1128\/AAC.03777-14","volume":"58","author":"MJ Dolton","year":"2014","unstructured":"Dolton MJ, Br\u00fcggemann RJM, Burger DM, McLachlan AJ (2014) Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. Antimicrob Agents Chemother 58(11):6879\u20136885. https:\/\/doi.org\/10.1128\/AAC.03777-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"9983_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2165\/00003088-200645050-00003","volume":"45","author":"M Jerling","year":"2006","unstructured":"Jerling M (2006) Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet 45(5):469\u2013491","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"9983_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1124\/dmd.116.074393","volume":"45","author":"RH Takahashi","year":"2017","unstructured":"Takahashi RH, Shahidi-Latham SK, Wong S, Chang JH (2017) Applying stable isotope labeled amino acids in micropatterned hepatocyte coculture to directly determine the degradation rate constant for CYP3A4. Drug Metab Dispos 45(6):581\u2013585. https:\/\/doi.org\/10.1124\/dmd.116.074393","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"9983_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2174\/138920008784746382","volume":"9","author":"J Yang","year":"2008","unstructured":"Yang J, Liao M, Shou M et al (2008) Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. CDM 9(5):384\u2013393. https:\/\/doi.org\/10.2174\/138920008784746382","journal-title":"CDM"},{"key":"9983_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jpba.2018.04.003","volume":"155","author":"D Busch","year":"2018","unstructured":"Busch D, Fritz A, Partecke LI, Heidecke CD, Oswald S (2018) LC\u2013MS\/MS method for the simultaneous quantification of intestinal CYP and UGT activity. J Pharm Biomed Anal 155:194\u2013201. https:\/\/doi.org\/10.1016\/j.jpba.2018.04.003","journal-title":"J Pharm Biomed Anal"},{"key":"9983_CR26","doi-asserted-by":"publisher","unstructured":"Zhang H, Gao N, Tian X, et al (2015) Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo. Sci Rep 5. https:\/\/doi.org\/10.1038\/srep17671","DOI":"10.1038\/srep17671"},{"issue":"15\u201316","key":"9983_CR27","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1002\/pmic.201500433","volume":"16","author":"K Nakamura","year":"2016","unstructured":"Nakamura K, Hirayama-Kurogi M, Ito S et al (2016) Large-scale multiplex absolute protein quantification of drug-metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATH-MS: Comparison with MRM\/SRM and HR-MRM\/PRM. Proteomics 16(15\u201316):2106\u20132117. https:\/\/doi.org\/10.1002\/pmic.201500433","journal-title":"Proteomics"},{"key":"9983_CR28","doi-asserted-by":"publisher","unstructured":"Drinking Water and Health, Volume 8: Pharmacokinetics in Risk Assessment. National Academies Press; 1987. https:\/\/doi.org\/10.17226\/1015","DOI":"10.17226\/1015"},{"issue":"9","key":"9983_CR29","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1124\/dmd.115.065326","volume":"43","author":"D Ramsden","year":"2015","unstructured":"Ramsden D, Zhou J, Tweedie DJ (2015) Determination of a Degradation Constant for CYP3A4 by Direct Suppression of mRNA in a Novel Human Hepatocyte Model. HepatoPac Drug Metab Dispos 43(9):1307\u20131315. https:\/\/doi.org\/10.1124\/dmd.115.065326","journal-title":"HepatoPac Drug Metab Dispos"},{"issue":"1","key":"9983_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jps.10005","volume":"91","author":"P Poulin","year":"2002","unstructured":"Poulin P, Theil FP (2002) Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. Journal of Pharmaceutical Sciences. 91(1):129\u2013156","journal-title":"Journal of Pharmaceutical Sciences."},{"issue":"5","key":"9983_CR31","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/jps.10128","volume":"91","author":"P Poulin","year":"2002","unstructured":"Poulin P, Theil FP (2002) Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. Journal of Pharmaceutical Sciences 91(5):1358\u20131370","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"6","key":"9983_CR32","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/jps.20073","volume":"93","author":"LM Berezhkovskiy","year":"2004","unstructured":"Berezhkovskiy LM (2004) Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 93(6):1628\u20131640. https:\/\/doi.org\/10.1002\/jps.20073","journal-title":"J Pharm Sci"},{"key":"9983_CR33","unstructured":"Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Published online 2018. https:\/\/www.cdc.gov\/nchs\/nhanes\/ Accessed 30 Aug 2018"},{"issue":"3","key":"9983_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0146-6453(03)00002-2","volume":"32","author":"J Valentin","year":"2002","unstructured":"Valentin J (2002) Basic anatomical and physiological data for use in radiological protection: reference values: ICRP Publication 89. Ann ICRP 32(3):1\u2013277. https:\/\/doi.org\/10.1016\/S0146-6453(03)00002-2","journal-title":"Ann ICRP"},{"issue":"9","key":"9983_CR35","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3109\/10408444.2012.709225","volume":"42","author":"S Bosgra","year":"2012","unstructured":"Bosgra S, van Eijkeren J, Bos P, Zeilmaker M, Slob W (2012) An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry. Crit Rev Toxicol 42(9):751\u2013767. https:\/\/doi.org\/10.3109\/10408444.2012.709225","journal-title":"Crit Rev Toxicol"},{"issue":"7","key":"9983_CR36","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1002\/jps.24011","volume":"103","author":"CD Ruark","year":"2014","unstructured":"Ruark CD, Hack CE, Robinson PJ, Mahle DA, Gearhart JM (2014) Predicting passive and active tissue: plasma partition coefficients: interindividual and interspecies variability. J Pharm Sci 103(7):2189\u20132198. https:\/\/doi.org\/10.1002\/jps.24011","journal-title":"J Pharm Sci"},{"issue":"1","key":"9983_CR37","doi-asserted-by":"publisher","first-page":"9709","DOI":"10.1038\/s41598-019-45778-9","volume":"9","author":"MK Ladumor","year":"2019","unstructured":"Ladumor MK, Thakur A, Sharma S et al (2019) A repository of protein abundance data of drug metabolizing enzymes and transporters for applications in physiologically based pharmacokinetic (PBPK) modelling and simulation. Sci Rep 9(1):9709. https:\/\/doi.org\/10.1038\/s41598-019-45778-9","journal-title":"Sci Rep"},{"issue":"5","key":"9983_CR38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1248\/yakushi.123.369","volume":"123","author":"M Nishimura","year":"2003","unstructured":"Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T (2003) Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessedby high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123(5):369\u2013375. https:\/\/doi.org\/10.1248\/yakushi.123.369","journal-title":"Yakugaku Zasshi"},{"key":"9983_CR39","doi-asserted-by":"publisher","unstructured":"Peters SA (2012) Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations. 1st ed. John Wiley & Sons, Ltd. https:\/\/doi.org\/10.1002\/9781118140291","DOI":"10.1002\/9781118140291"},{"issue":"4","key":"9983_CR40","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/074823379701300401","volume":"13","author":"RP Brown","year":"1997","unstructured":"Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13(4):407\u2013484","journal-title":"Toxicol Ind Health"},{"key":"9983_CR41","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Published online 2021. https:\/\/www.R-project.org\/"},{"key":"9983_CR42","unstructured":"Baron KT. mrgsolve: Simulate from ODE-Based Models. https:\/\/mrgsolve.org\/docs\/"},{"key":"9983_CR43","unstructured":"Ypma J, Johnson SG. The NLopt nonlinear-optimization package. Published online 2008. https:\/\/github.com\/stevengj\/nlopt"},{"issue":"12","key":"9983_CR44","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/psp4.12467","volume":"8","author":"A Elmokadem","year":"2019","unstructured":"Elmokadem A, Riggs MM, Baron KT (2019) Quantitative systems pharmacology and physiologically-based pharmacokinetic modeling with mrgsolve: a hands-on tutorial. CPT: Pharmacometrics & Systems Pharmacology 8(12):883\u2013893. https:\/\/doi.org\/10.1002\/psp4.12467","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"9983_CR45","unstructured":"Cytochrome P450 3A4 human E. coli 9035-51-2. https:\/\/www.sigmaaldrich.com\/US\/en\/product\/sigma\/h5042. Accessed 16 Dec 2024"},{"issue":"1","key":"9983_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/psp4.12479","volume":"9","author":"C Kuemmel","year":"2020","unstructured":"Kuemmel C, Yang Y, Zhang X et al (2020) Consideration of a credibility assessment framework in model-informed drug development: potential application to physiologically-based pharmacokinetic modeling and simulation. CPT: Pharmacometrics & Systems Pharmacology 9(1):21\u201328. https:\/\/doi.org\/10.1002\/psp4.12479","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"D1","key":"9983_CR47","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart DS, Feunang YD, Guo AC et al (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Research 46(D1):D1074\u2013D1082. https:\/\/doi.org\/10.1093\/nar\/gkx1037","journal-title":"Nucleic Acids Research"},{"key":"9983_CR48","unstructured":"Ranexa (previously Latixa): EPAR \u2013 Assessment Report. European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ranexa-epar-public-assessment-report_en.pdf. Accessed 2020-3-31.\u00a0Accessed 31 Mar 2020"},{"issue":"5","key":"9983_CR49","doi-asserted-by":"publisher","first-page":"643","DOI":"10.4155\/tde.11.19","volume":"2","author":"JA Y\u00e1\u00f1ez","year":"2011","unstructured":"Y\u00e1\u00f1ez JA, Remsberg CM, Sayre CL, Forrest ML, Davies NM (2011) Flip-flop pharmacokinetics \u2013 delivering a reversal of disposition: challenges and opportunities during drug development. Ther Deliv 2(5):643\u2013672. https:\/\/doi.org\/10.4155\/tde.11.19","journal-title":"Ther Deliv"},{"issue":"2","key":"9983_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1124\/dmd.109.028746","volume":"38","author":"SK Quinney","year":"2010","unstructured":"Quinney SK, Zhang X, Lucksiri A, Gorski JC, Li L, Hall SD (2010) Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos 38(2):241\u2013248. https:\/\/doi.org\/10.1124\/dmd.109.028746","journal-title":"Drug Metab Dispos"},{"key":"9983_CR51","unstructured":"Noxafil-H-C-610-II-0062: EPAR \u2013 Assessment Report \u2013 Variation. European Medicines Agency. 16 September 2021. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/noxafil-h-c-610-ii-0062-epar-assessment-report-variation_en.pdf."},{"key":"9983_CR52","unstructured":"Noxafil PowerPowder Mix Kit: Center for Drug Evaluation and Research Multi-Discipline Review. Application Number 214770Orig1s000. 28 May 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/214770Orig1s000MultidisciplineR.pdf."},{"issue":"5","key":"9983_CR53","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/jat\/bkv030","volume":"39","author":"DE Moody","year":"2015","unstructured":"Moody DE, Liu F, Fang WB (2015) Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism. J Anal Toxicol 39(5):374\u2013386. https:\/\/doi.org\/10.1093\/jat\/bkv030","journal-title":"J Anal Toxicol"},{"issue":"7","key":"9983_CR54","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/00498254.2018.1473662","volume":"49","author":"X Luo","year":"2019","unstructured":"Luo X, Li T, Yu Z et al (2019) The impact of azole antifungal drugs on imatinib metabolism in human liver microsomes. Xenobiotica 49(7):753\u2013761. https:\/\/doi.org\/10.1080\/00498254.2018.1473662","journal-title":"Xenobiotica"},{"issue":"3","key":"9983_CR55","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/17425255.2018.1440287","volume":"14","author":"C Smit","year":"2018","unstructured":"Smit C, Hoogd SD, Br\u00fcggemann RJM, Knibbe CAJ (2018) Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol 14(3):275\u2013285. https:\/\/doi.org\/10.1080\/17425255.2018.1440287","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"9","key":"9983_CR56","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1038\/psp.2012.3","volume":"1","author":"W Huisinga","year":"2012","unstructured":"Huisinga W, Solms A, Fronton L, Pilari S (2012) Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling. CPT Pharmacometrics Syst Pharmacol 1(9):e4. https:\/\/doi.org\/10.1038\/psp.2012.3","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-09983-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-025-09983-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-09983-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:33:12Z","timestamp":1757255592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-025-09983-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["9983"],"URL":"https:\/\/doi.org\/10.1007\/s10928-025-09983-6","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CDB and CRC are employees of Emerald Lake Safety, LLC. DJG is supported in part by grant UM1 TR004398 from the National Institutes of Health, Department of Health and Human Services. The BOW-001 and BOW-002 studies were funded by Emerald Lake Safety, LLC and followed ethical guidelines as described in the original study publications.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}